A two-stage matched case-control study on multiple hypertensive candidate genes in Han Chinese

Tai-Yue Kuo1, Mei-Jyh Kang, Jaw-Wen Chen

  • 1Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

Insights

This study identified two novel single-nucleotide polymorphisms (SNPs) associated with young-onset hypertension in Han Chinese in Taiwan. These genetic markers in GNB3 and INSR genes offer new insights into hypertension risk factors.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Population Health

Background:

  • Hypertension affects over a billion people globally, contributing to significant mortality from stroke and cardiovascular diseases.
  • In Taiwan, approximately 3.8 million adults have hypertension, highlighting its public health importance.
  • Hypertension is a critical risk factor for severe health outcomes, including stroke, cardiovascular disease, and end-stage renal disease, causing over 13.5 million deaths annually worldwide.

Purpose of the Study:

  • To investigate genetic associations with young-onset hypertension in a Han Chinese population in Taiwan.
  • To identify novel single-nucleotide polymorphisms (SNPs) linked to hypertension susceptibility.
  • To explore the role of candidate genes in the development of hypertension.

Main Methods:

  • A two-stage association study was conducted using genotype data from 992 young-onset hypertensive cases and 992 matched controls.
  • Genomic analysis focused on 238 single-nucleotide polymorphisms (SNPs) within 36 established hypertension candidate genes.
  • Conditional logistic regression was employed for association analysis.

Main Results:

  • Two SNPs demonstrated strong associations with hypertension in both study stages.
  • rs2301339, located in the guanine nucleotide-binding protein β3 subunit (GNB3) gene, was identified as a significant risk factor.
  • rs17254521, situated in the insulin receptor (INSR) gene, was also significantly associated with hypertension.

Conclusions:

  • This research identified a novel SNP in GNB3 (rs2301339) and a novel SNP in INSR (rs17254521) associated with young-onset hypertension.
  • The identified GNB3 SNP (rs2301339) is in linkage disequilibrium with rs5443, showing an opposite effect compared to previous findings in Caucasian populations.
  • Further replication studies with larger sample sizes are recommended to validate these findings and their clinical implications.
Abstract

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...